Team:NTU-Singapore/Project

From 2008.igem.org

(Difference between revisions)
Line 13: Line 13:
-
The focus of the NTU @ iGEM Team's project is the use of bacteriocins (i.e. colicin E7) for the killing of the <i>Escherichia Coli</i> O157:H7 enterohemorrhagic strain (EHEC), which causes symptoms such as bloody diarrhea. This is a prevalent medical problem that has a reach of a wide population. The team intends to achieve its objective by engineering a biological system that:<br><br>
+
The focus of the NTU @ iGEM Team's project is the use of bacteriocins (i.e. colicin E7) for the killing of the <i>Escherichia Coli</i> O157:H7 enterohemorrhagic strain (EHEC), which causes symptoms such as bloody diarrhea and kidney failure. This is a prevalent medical problem that has a reach of a wide population. The team intends to achieve its objective by engineering a biological system that:<br><br>
i) produces Colicin E7,<br>  
i) produces Colicin E7,<br>  
ii) detects the symptoms (e.g. blood) and presence of pathogenic E-Coli, and <br>
ii) detects the symptoms (e.g. blood) and presence of pathogenic E-Coli, and <br>
iii) releases E7 through lysis. <br>
iii) releases E7 through lysis. <br>
<br>
<br>
-
The system will be developed using the following proposed protocol: Colicin E7 production is achieved by the insertion of the colicin E7 gene and colicin immunity gene downstream of and under regulation of the <i>lacI</i> gene, found in wild type E. Coli K12 strain. The production of the lysis protein functions under the control of an AND gate, constructed by two plasmids, and whose inputs are presence of Fe<sup>2+</sup> ions  (attributed to presence of blood) and AI-2 (attributed to presence of O157:H7). <br><br><i>LuxS</i> knock-out was carried out to eliminate AI-2 production of K12, obtaining mutant W3110 strain, thus ensuring that AI-2 detected is purely from O157:H7. Upon detection of Fe<sup>2+</sup> ions, T7ptag expression is initiated producing T7 RNA Polymerase. Upon detection of phosphorylated AI-2, expression of the <i>supD</i> gene is initiated by activation of promoter <i>lsrA</i>, producing amber suppressor tRNA. In combination, the two upstream inputs activate the expression of the lysis protein gene, under the influence of R6K origin, resulting in amplified response of the AND gate. <br><br>The team also intends to characterize the various parts and devices used in the project, in terms of sensitivity to temperature and input concentrations by fluorescence assay and Western blotting. The team will conduct the modeling of the systems.
+
The system will be developed using the following proposed protocol: Colicin E7 production is achieved by the insertion of the colicin E7 gene and colicin immunity gene downstream of and under regulation of the <i>lacI</i> gene, found in wild type E. Coli K12 strain. The production of the lysis protein functions under the control of an AND gate, constructed by two plasmids, and whose inputs are presence of Fe<sup>2+</sup> ions  (attributed to presence of blood) and AI-2 (attributed to presence of O157:H7). <br><br>
-
</html>
+
 +
The team's aim is to control the level of colicin production in the engineered bacteria. The engineered bacteria should also be able to be accurate in its detection.
 +
 +
<i>LuxS</i> knock-out was carried out to eliminate AI-2 production of K12, obtaining mutant W3110 strain, thus ensuring that AI-2 detected is purely from O157:H7. Upon detection of Fe<sup>2+</sup> ions, T7ptag expression is initiated producing T7 RNA Polymerase. Upon detection of phosphorylated AI-2, expression of the <i>supD</i> gene is initiated by activation of promoter <i>lsrA</i>, producing amber suppressor tRNA. In combination, the two upstream inputs activate the expression of the lysis protein gene, under the influence of R6K origin, resulting in amplified response of the AND gate. <br><br>The team also intends to characterize the various parts and devices used in the project, in terms of sensitivity to temperature and input concentrations by fluorescence assay and Western blotting. The team will conduct the modeling of the systems.
 +
</html>
 +
<br>
The team will employ the methodology derived from basic engineering concepts: Abstraction, decoupling and standardization.
The team will employ the methodology derived from basic engineering concepts: Abstraction, decoupling and standardization.
-
='''G.O.T Colincin?'''=
 
[[Image:NTU_Comic_2.jpg|thumb|center|900px|G.O.T colicin?]]
[[Image:NTU_Comic_2.jpg|thumb|center|900px|G.O.T colicin?]]
-
Our group has decided to engineer E.coli as a carrier for ''colicin E7'' to deal with the pathogenic strain of Ecoli known as ''Escherichia coli O157:H7''.
 
-
Escherichia coli O157:H7 is an ''enterohemorrhagic strain'' that can cause bloody diarrhea and kidney failure. Current methods of cure for the infection include blood transfusion and dialysis. Currently no antibiotic is able to kill it.
 
-
 
-
Our approach is to use ''Colicin E7'' to kill this harmful strain of bacteria. We intend to use our very own genetically engineered E.coli as the carrier of the colicin. We also wish for our bacteria to able to detect the presence of blood and the bacteria before it releases the colicins to eradicate the pathogen.
 
-
 
-
Our aim would be to control the level of colicin production in our bacteria. Our engineered bacteria should also be able to be accurate in its detection.
 
For any comments or enquiries, feel free to contact us at [mailto:ntu.igem@gmail.com ntu.igem@gmail.com]
For any comments or enquiries, feel free to contact us at [mailto:ntu.igem@gmail.com ntu.igem@gmail.com]

Revision as of 14:11, 26 October 2008



Introduction

ENGINEERING COLICIN E7 PRODUCTION SYSTEM TO KILL ENTEROHEMORRHAGIC ESCHERICHIA COLI O157:H7 (EHEC) VIA THE DETECTION OF EHEC SYMPTOMS


The focus of the NTU @ iGEM Team's project is the use of bacteriocins (i.e. colicin E7) for the killing of the Escherichia Coli O157:H7 enterohemorrhagic strain (EHEC), which causes symptoms such as bloody diarrhea and kidney failure. This is a prevalent medical problem that has a reach of a wide population. The team intends to achieve its objective by engineering a biological system that:

i) produces Colicin E7,
ii) detects the symptoms (e.g. blood) and presence of pathogenic E-Coli, and
iii) releases E7 through lysis.

The system will be developed using the following proposed protocol: Colicin E7 production is achieved by the insertion of the colicin E7 gene and colicin immunity gene downstream of and under regulation of the lacI gene, found in wild type E. Coli K12 strain. The production of the lysis protein functions under the control of an AND gate, constructed by two plasmids, and whose inputs are presence of Fe2+ ions (attributed to presence of blood) and AI-2 (attributed to presence of O157:H7).

The team's aim is to control the level of colicin production in the engineered bacteria. The engineered bacteria should also be able to be accurate in its detection. LuxS knock-out was carried out to eliminate AI-2 production of K12, obtaining mutant W3110 strain, thus ensuring that AI-2 detected is purely from O157:H7. Upon detection of Fe2+ ions, T7ptag expression is initiated producing T7 RNA Polymerase. Upon detection of phosphorylated AI-2, expression of the supD gene is initiated by activation of promoter lsrA, producing amber suppressor tRNA. In combination, the two upstream inputs activate the expression of the lysis protein gene, under the influence of R6K origin, resulting in amplified response of the AND gate.

The team also intends to characterize the various parts and devices used in the project, in terms of sensitivity to temperature and input concentrations by fluorescence assay and Western blotting. The team will conduct the modeling of the systems.
The team will employ the methodology derived from basic engineering concepts: Abstraction, decoupling and standardization.


G.O.T colicin?



For any comments or enquiries, feel free to contact us at ntu.igem@gmail.com